JonesResearch analyst Justin Walsh lowered the firm’s price target on TriSalus Life Sciences to $11 from $16 and keeps a Buy rating on the shares following the Q2 report. The firm remains confident in the potential of both TriNav and nelitolimod, but reduced risk-adjusted revenue estimates for nelitolimod following its deprioritized development in hepatocellular carcinoma and intrahepatic cholangiocarcinoma .
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
Questions or Comments about the article? Write to editor@tipranks.com